Changchun High-tech: Subsidiary GS3-007a's domestic production drug registration clinical trial application has been accepted

Changchun High-tech Announcement: A subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received an "Acceptance Notice" issued by the National Medical Products Administration for the domestic production drug registration clinical trial application of GS3-007a Dry Powder for Oral Suspension. GS3-007a Dry Powder for Oral Suspension is a self-developed oral small molecule growth hormone secretion stimulant drug by Jinsai Pharmaceutical, classified as Category 1 chemical drug, intended for the treatment of children with slow growth caused by a lack of endogenous growth hormone. Currently, there are no similar products on the market in China. The acceptance of this clinical trial application can facilitate further clinical development of the product and meet the unmet clinical needs of patients.